European obesity group says incretin drugs like semaglutide should not replace broader care
A European obesity group says drugs like semaglutide and tirzepatide belong alongside nutrition, activity and follow-up care, guidance that does not change US prescriptions or coverage.
The European Association for the Study of Obesity has published a position statement on how incretin-based obesity medicines — the drug class that includes semaglutide (sold as Ozempic, Wegovy and Rybelsus) and tirzepatide (sold as Mounjaro and Zepbound) — should sit within comprehensive obesity care rather than replace it [1]. The statement appeared in The Lancet Regional Health – Europe on September 3, 2026 [1].
The document is written for European clinical practice, and it addresses four areas alongside pharmacotherapy: nutrition, physical activity, psychological support and long-term follow-up [1]. That is the core of its argument. The medicines are treated as one component of obesity management, not as a stand-alone answer [1].
For readers in the United States, the first thing to know is what the statement is not. It is guidance from a professional association, and it carries no regulatory force in the United States [1]. It does not change FDA-approved labeling for semaglutide or tirzepatide, does not alter prescribing rules, and does not change what insurers or pharmacy benefit managers cover [1].
Several specifics are not yet established. Whether the statement sets numerical follow-up intervals, monitoring schedules, or thresholds for starting or stopping treatment has not been reported [1]. Its position on oral incretin agents such as orforglipron (Foundayo) has not been reported [1]. Whether other European medical societies have endorsed the document, and how EASO reviewed the evidence behind it, have not been disclosed [1].
EASO frames the statement as guidance for European practice [1]. It does not address US pricing, insurance coverage or drug supply, and whether it sets eligibility criteria for treatment has not been reported [1].
Why it matters for patients
No one's prescription changes because of this document. US clinicians work from FDA labeling and their own professional guidelines, and a European association statement has no regulatory effect here [1].
The practical signal is about what surrounds the medicine. The statement puts nutrition, physical activity, psychological support and long-term follow-up on the same footing as drug treatment [1]. That framing is relevant for people who expect to stay on these medicines for extended periods, because follow-up and non-drug support are presented as part of the model of care rather than optional extras [1].
It is also a reminder that the drugs are the subject of active guideline debate rather than settled practice. How a European position statement might apply to an individual's care is a clinical question, and this document does not settle it for US practice [1].
What happens next
No US regulatory action tied to the statement has been announced [1]. Whether European regulators, health systems or insurers will adopt any part of it has not been reported [1]. The statement is published and stands as guidance from EASO [1].
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.